
Taiho buys Swiss biotech and its ADC tech for $400M
Japan-based Taiho Pharmaceuticals on Monday said it will acquire Switzerland’s Araris Biotech and its antibody-drug conjugate technology for $400 million upfront. The two companies have worked together since 2023, when they agreed to use Araris’ technology …